185 related articles for article (PubMed ID: 34433303)
1. Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.
Chevli KK; Shore ND; Trainer A; Smith AB; Saltzstein D; Ehrlich Y; Raman JD; Friedman B; D'Anna R; Morris D; Hu B; Tyson M; Sankin A; Kates M; Linehan J; Scherr D; Kester S; Verni M; Chamie K; Karsh L; Cinman A; Meads A; Lahiri S; Malinowski M; Gabai N; Raju S; Schoenberg M; Seltzer E; Huang WC
J Urol; 2022 Jan; 207(1):61-69. PubMed ID: 34433303
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
Prasad SM; Huang WC; Shore ND; Hu B; Bjurlin M; Brown G; Genov P; Shishkov D; Khuskivadze A; Ganev T; Marchev D; Orlov I; Kopyltsov E; Zubarev V; Nosov A; Komlev D; Burger B; Raju S; Meads A; Schoenberg M
J Urol; 2023 Oct; 210(4):619-629. PubMed ID: 37548555
[TBL] [Abstract][Full Text] [Related]
3. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report.
Matin SF; Pierorazio PM; Kleinmann N; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky SG; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Seltzer E; Schoenberg M; Lerner SP
J Urol; 2022 Apr; 207(4):779-788. PubMed ID: 34915741
[TBL] [Abstract][Full Text] [Related]
4. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Kleinmann N; Matin SF; Pierorazio PM; Gore JL; Shabsigh A; Hu B; Chamie K; Godoy G; Hubosky S; Rivera M; O'Donnell M; Quek M; Raman JD; Knoedler JJ; Scherr D; Stern J; Weight C; Weizer A; Woods M; Kaimakliotis H; Smith AB; Linehan J; Coleman J; Humphreys MR; Pak R; Lifshitz D; Verni M; Adibi M; Amin MB; Seltzer E; Klein I; Konorty M; Strauss-Ayali D; Hakim G; Schoenberg M; Lerner SP
Lancet Oncol; 2020 Jun; 21(6):776-785. PubMed ID: 32631491
[TBL] [Abstract][Full Text] [Related]
5. Minimal Patient-Reported Side Effects for a Chemoablative Gel (UGN-102) Used as Frontline Treatment in Adults with Nonmuscle-Invasive Bladder Cancer.
Stover AM; Basak R; Mueller D; Lipman R; Teal R; Hilton A; Giannone K; Waheed M; Smith AB
J Urol; 2022 Sep; 208(3):580-588. PubMed ID: 35640276
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
7. CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Mostafid AH; Porta N; Cresswell J; Griffiths TRL; Kelly JD; Penegar SR; Davenport K; McGrath JS; Campain N; Cooke P; Masood S; Knowles MA; Feber A; Knight A; Catto JWF; Lewis R; Hall E
BJU Int; 2020 Jun; 125(6):817-826. PubMed ID: 32124514
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Labbate C; Woldu S; Murray K; Rose K; Sexton W; Tachibana I; Kaimakliotis H; Jacob J; Dickstein R; Linehan J; Nieder A; Bjurlin M; Humphreys M; Ghodoussipour S; Quek M; O'Donnell M; Eisner B; Feldman A; Lotan Y; Matin SF
J Urol; 2023 May; 209(5):872-881. PubMed ID: 36657029
[TBL] [Abstract][Full Text] [Related]
9. The role of continuous saline bladder irrigation after transurethral resection in patients with high-grade non-muscle-invasive bladder cancer.
Onishi T; Sekito S; Shibahara T; Uchida K; Sasaki T
Scand J Urol; 2018; 52(5-6):385-388. PubMed ID: 30628540
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma.
Shabsigh A; Kleinmann N; Smith AB; Scherr D; Seltzer E; Schoenberg M; Lerner SP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):799-805. PubMed ID: 33677615
[TBL] [Abstract][Full Text] [Related]
12. Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Rosen GH; Nallani A; Muzzey C; Murray KS
J Urol; 2022 Jun; 207(6):1302-1311. PubMed ID: 35130080
[TBL] [Abstract][Full Text] [Related]
13. Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure.
Juvet T; Mari A; Lajkosz K; Wallis CJ; Kuk C; Erlich A; Krimus L; Fleshner NE; Kulkarni GS; Zlotta AR
Urol Oncol; 2020 Nov; 38(11):850.e9-850.e15. PubMed ID: 32712139
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.
Tan WS; Prendergast A; Ackerman C; Yogeswaran Y; Cresswell J; Mariappan P; Phull J; Hunter-Campbell P; Lazarowicz H; Mishra V; Rane A; Davies M; Warburton H; Cooke P; Mostafid H; Wilby D; Mills R; Issa R; Kelly JD
Eur Urol; 2023 Jun; 83(6):497-504. PubMed ID: 35999119
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review and Meta-analysis of Chemoablation for Non-muscle-invasive Bladder Cancer.
Yanagisawa T; Quhal F; Kawada T; Mostafaei H; Motlagh RS; Laukhtina E; Rajwa P; Deimling MV; Bianchi A; Pallauf M; Majdoub M; Pradere B; Moschini M; Karakiewicz PI; Teoh JY; Miki J; Kimura T; Shariat SF
Eur Urol Focus; 2023 May; 9(3):463-479. PubMed ID: 36517409
[TBL] [Abstract][Full Text] [Related]
16. DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Lindgren MS; Hansen E; Azawi N; Nielsen AM; Dyrskjøt L; Jensen JB
J Clin Oncol; 2023 Jan; 41(2):206-211. PubMed ID: 36223555
[TBL] [Abstract][Full Text] [Related]
17. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
18. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.
Lindgren MS; Bue P; Azawi N; Blichert-Refsgaard L; Sundelin MO; Dyrskjøt L; Jensen JB
Eur Urol; 2020 Dec; 78(6):856-862. PubMed ID: 32736928
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
[TBL] [Abstract][Full Text] [Related]
20. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
